Tirzepatide works by activating two different gut hormone receptors with one molecule: the GIP receptor and the GLP-1 receptor. That dual action is the accepted explanation for the size of the effect measured in SURMOUNT-1, where 2539 adults with obesity or overweight and no diabetes lost a mean 20.9% of body weight on tirzepatide 15 mg over 72 weeks, against 3.1% on placebo (PMID 35658024).
What is less settled is why two receptors beat one. This article works through the pharmacology that is established, the parts that are still argued about, and the trial evidence that complicates the simple version of the story.
- Tirzepatide agonises both the GIP and the GLP-1 receptor. Semaglutide and liraglutide only agonise the GLP-1 receptor.
- Laboratory work indicates it occupies the GIP receptor more than the GLP-1 receptor, and signals differently at the GLP-1 receptor than GLP-1 itself does.
- A C20 fatty diacid chain binds it to albumin, holding the half-life at about five to six days and allowing once-weekly injection.
- Steady-state blood levels arrive after roughly four weeks, but the labelled dose ladder takes at least 20 weeks to reach 15 mg.
- The neat explanation that GIP adds appetite suppression is not what the mechanistic substudies found, and a drug that blocks GIP receptors also produces substantial weight loss.
One peptide, two receptors
GIP and GLP-1 are both incretins: hormones released by the gut after eating that tell the pancreas food is arriving. Their receptors sit on pancreatic beta cells and in the brain, and for decades GLP-1 was the one drug developers pursued, because GIP-based approaches had produced disappointing results in type 2 diabetes.
Tirzepatide was built to test whether adding GIP activity to GLP-1 activity would do more than GLP-1 alone. It is a synthetic peptide carrying a fatty acid modification, designed from the start for weekly subcutaneous dosing. In the work that introduced it, the molecule activated both receptors in cell assays, produced glucose-dependent insulin secretion in mice through both receptors, and lowered body weight and food intake in mice more than a GLP-1 receptor agonist did (PMID 30473097).
The same paper carried the first human data. In a four-week study in healthy volunteers, weight differences against placebo reached 5.09 kg at a 4.5 mg dose, and in a four-week proof-of-concept study in people with type 2 diabetes, 10 mg and 15 mg significantly lowered fasting serum glucose. Those are four-week figures in small groups, not weight-loss results, but they were enough to justify the phase 3 programme.
What imbalanced and biased actually mean
Tirzepatide is usually described in the literature as an imbalanced, biased dual agonist. Both words are doing specific work, and neither means what it sounds like.
Imbalanced refers to how much of each receptor the drug occupies at clinically effective doses. Calculating that occupancy showed a greater degree of engagement at the GIP receptor than at the GLP-1 receptor (PMID 32730231). Tirzepatide is not a balanced fifty-fifty agonist. It leans towards GIP.
Biased refers to which internal signals a receptor sends once the drug is bound. At the GIP receptor, tirzepatide behaves much like native GIP. At the GLP-1 receptor it does not: it favours cAMP generation over recruitment of a protein called beta-arrestin, and it drives less receptor internalisation than GLP-1 does. In isolated pancreatic islets, beta-arrestin1 limited the insulin response to GLP-1 but not to GIP or tirzepatide, which suggests this bias is part of why the insulin response is larger.
That is a meaningful distinction for anyone comparing drugs. Tirzepatide is not semaglutide with a second receptor bolted on. It engages the shared receptor differently as well.
Why one injection lasts a week
The pharmacokinetics are the least contested part of the mechanism and the part that explains most of the practical experience of taking the drug.
| Property | Value on the label | What follows from it |
|---|---|---|
| Absolute bioavailability | 80% | Most of an injected dose reaches the circulation |
| Time to peak concentration | Median 24 hours, range 8 to 72 hours | No sharp peak after dosing, so no daily timing to manage |
| Plasma albumin binding | 99% | The fatty diacid tail keeps the drug parked on albumin rather than clearing |
| Elimination half-life | About 5 to 6 days | One weekly injection keeps levels continuous rather than pulsed |
| Time to steady state | About 4 weeks of weekly dosing | Each new dose takes a month to reach its full blood level |
| Exposure by injection site | Similar in abdomen, thigh and upper arm | Site choice does not change the dose delivered |
The C20 fatty diacid is the engineering trick. Peptides of this size are cleared from the blood within minutes to hours. Binding almost entirely to albumin turns a peptide into something that clears over days, which is what makes weekly dosing possible at all. It is eventually broken down by cleavage of the peptide backbone, oxidation of that fatty acid chain and amide hydrolysis, with the fragments leaving in urine and faeces.
The four-week steady state has a practical consequence that gets missed. Someone who moves up a dose step is not at the full blood level of the new dose for about a month, which is roughly the same length as the step itself. Every escalation is therefore a moving target rather than a plateau.
What the receptors do downstream
Four effects are consistently attributed to this receptor pair, and they act on different problems.
- Glucose-dependent insulin release. Both receptors amplify insulin secretion when blood glucose is high and stop amplifying it when glucose is normal. That dependence is why the phase 3 diabetes trials recorded almost no severe hypoglycaemia on tirzepatide alone.
- Suppressed glucagon when glucose is high. Less glucagon means less glucose released by the liver, which is a separate route to the same glycaemic result.
- Slower gastric emptying. Food leaves the stomach more slowly, which blunts the post-meal glucose rise and produces the sensation of fullness people describe.
- Reduced appetite and food intake. Receptors in the brain, not the gut, are thought to carry this part, and it is the effect that produces sustained weight loss rather than a glycaemic improvement.
Those four mechanisms also explain the side effect profile, because slowed gastric emptying and reduced appetite are not separable from nausea and reflux in a dose-dependent way. The rates the trials recorded are in tirzepatide side effects.
How fast does it work?
Two different answers, and mixing them up is where most of the confusion about timing comes from.
The pharmacological answer is about four weeks, the time to steady state at any given dose. The clinical answer is much longer, because the label starts at 2.5 mg and the ceiling is 15 mg, increased in 2.5 mg steps no sooner than every four weeks. The earliest anyone can be at 15 mg is week 21. SURMOUNT-1 wrote a 20-week escalation into its protocol for that reason, so its 72-week averages include five months during which most participants had not yet reached their assigned dose.
This is why a weight curve looks flat against the headline percentage in the first few months and then steepens. The headline is a 72-week figure from a dose that was not reached until week 21. The full ladder, and what each rung has been measured at, is in the tirzepatide dosage chart. The glycaemic side of the same molecule, where the dose responds to HbA1c rather than to a target, is in the Mounjaro dosage chart.
See what the trial percentages mean for you
SURMOUNT-1 reported 15.0%, 19.5% and 20.9%. Run your own starting weight against those curves instead of reading them as abstractions.
Does the GIP half explain the bigger numbers?
The intuitive story is that GIP adds appetite suppression on top of GLP-1, so people eat less and lose more. Two pieces of evidence make that harder to hold.
The first is a mechanistic substudy of a head-to-head trial in people with type 2 diabetes, which measured body composition, appetite and energy intake at baseline and week 28 on tirzepatide 15 mg, semaglutide 1 mg or placebo (PMID 36857477). Tirzepatide produced significantly more weight loss than either comparator and more fat mass reduction. But both drugs reduced appetite compared with placebo, and appetite scores and energy intake reductions did not differ between tirzepatide and semaglutide. The authors concluded that the difference in food intake at an ad libitum meal was not sufficient to explain the difference in weight outcomes.
The second is stranger. Maridebart cafraglutide is a once-monthly molecule that agonises the GLP-1 receptor and antagonises the GIP receptor, the opposite of what tirzepatide does at that receptor. In a phase 2 trial of 592 participants, mean weight change at 52 weeks ranged from -12.3% to -16.2% in the obesity cohort against -2.5% on placebo (PMID 40549887).
So blocking the GIP receptor and activating it both produce substantial weight loss alongside GLP-1 agonism. Whatever GIP is contributing, a simple additive model of appetite suppression does not capture it, and the honest position is that the mechanism behind tirzepatide's margin is still being worked out. That uncertainty does not affect the trial results, which are what they are, but it should make anyone cautious about mechanistic claims that sound tidier than the evidence.
What the mechanism does not tell you
- Whether it will work for a given person. In SURMOUNT-1, 57% of the 15 mg group lost at least 20% of their body weight and others lost far less, on the same dose for the same 72 weeks.
- Whether the loss holds after stopping. Receptor pharmacology stops when the drug clears, and the withdrawal trial data reflects that.
- How it compares with semaglutide for weight loss. SURPASS-2 compared it against a 1 mg diabetes dose, not the 2.4 mg weight-management dose. The randomised comparison that addresses this is in semaglutide vs tirzepatide.
- What the numbers mean for one person. A percentage is a population average. Running a starting weight through a GLP-1 weight loss calculator converts it into pounds, which is a more usable reference point than 20.9%.
FAQ
How does tirzepatide work?
Tirzepatide is a single peptide that activates two gut hormone receptors at once, the GIP receptor and the GLP-1 receptor. Between them those receptors increase insulin release when glucose is high, slow how quickly the stomach empties and reduce appetite. A C20 fatty diacid chain on the molecule binds it to albumin in the blood, which stretches the half-life to about five to six days and makes weekly injection possible.
Does tirzepatide work better than semaglutide?
In SURPASS-2, an open-label 40-week trial in 1879 adults with type 2 diabetes, tirzepatide beat semaglutide 1 mg on both HbA1c and weight, with weight differences of 1.9 kg, 3.6 kg and 5.5 kg at 5 mg, 10 mg and 15 mg. The comparator there was a 1 mg diabetes dose rather than the 2.4 mg weight-management dose, so it does not settle the question for weight loss. The randomised comparison that does is covered in our semaglutide versus tirzepatide article.
How fast does tirzepatide work?
Pharmacologically, within about a month: the label states that steady-state concentrations are reached after four weeks of once-weekly dosing. Clinically it takes much longer, because the starting dose is 2.5 mg and the labelled ceiling is 15 mg, reached no sooner than week 21. SURMOUNT-1 built a 20-week escalation into its design, so its 72-week averages include five months during which most participants were below their assigned dose.
Is tirzepatide a GLP-1?
Partly. It agonises the GLP-1 receptor, so it is often grouped with the GLP-1 drugs, but it also agonises the GIP receptor, which semaglutide and liraglutide do not. Laboratory work indicates it actually occupies the GIP receptor more than the GLP-1 receptor, which is why it is usually described as a dual agonist rather than a GLP-1 receptor agonist.
Is the GIP half the reason tirzepatide produces more weight loss?
That is the working hypothesis, not a settled finding. A head-to-head mechanistic substudy found tirzepatide 15 mg reduced appetite and energy intake no more than semaglutide 1 mg at 28 weeks, yet produced more weight and fat mass loss. And a separate drug that blocks the GIP receptor while agonising GLP-1 produced 12.3% to 16.2% weight loss over 52 weeks in a phase 2 trial, so both agonising and antagonising that receptor appear to work.
Does tirzepatide work if you do not have diabetes?
Yes, and the largest effects were recorded in that population. SURMOUNT-1 enrolled 2539 adults with obesity, or overweight with a weight-related complication, and no diabetes, and reported mean weight changes of 15.0%, 19.5% and 20.9% at 5 mg, 10 mg and 15 mg over 72 weeks against 3.1% on placebo.
Sources
- Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018;18:3-14. PMID: 30473097
- Willard FS, Douros JD, Gabe MB, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020;5(17):e140532. PMID: 32730231
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. PMID: 35658024
- Heise T, DeVries JH, Urva S, et al. Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes. Diabetes Care. 2023;46(5):998-1004. PMID: 36857477
- Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med. 2021;385(6):503-515. PMID: 34170647
- Jastreboff AM, Ryan DH, Bays HE, et al. Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity: A Phase 2 Trial. N Engl J Med. 2025;393(9):843-857. PMID: 40549887
- ZEPBOUND (tirzepatide) injection, prescribing information. Eli Lilly and Company. Sections 12.1 and 12.3, mechanism of action and pharmacokinetics.
This article is for information only and is not medical advice. Dosing, suitability and any change to treatment are decisions for your prescriber.